Anthony James Culverwell bought $30k of QNRX
director at Quoin Pharmaceuticals, Ltd.. 6,146 shares at an average of $4.88, traded Aug 31, 2026, filed Sep 1, 2026.
Score components
- +15RoleDirector
- +5Trade size$30k at market
- +3Relative to holdingsHoldings up 18%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-104402, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | POpen-market purchase ADSs | +6,146 | $4.88 | $30k | 40,364 | 42 d ago |
| Aug 31, 2026 | POpen-market purchase Ordinary Warrants (Right to Buy)derivative | +3,073 | - | - | 3,073 | 42 d ago |
Related signals
Other insiders at Quoin Pharmaceuticals, Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 55Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $100k 20,490 shares | +119% | |
| 54Moderate | Quoin Pharmaceuticals, Ltd. | Sally Bridget Lawlor Chief Financial Officer | $50k 10,244 shares | +2328% | |
| 60Notable | Quoin Pharmaceuticals, Ltd. | Michael Myers Chief Executive Officer | $100k 20,490 shares | +119% | |
| 44Moderate | QNRXbuy Quoin Pharmaceuticals, Ltd. | Dennis Langer director | $129k 15,152 shares | first purchase | |
| 58Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $250k 555,556 shares | +1180% | |
| 46Moderate | Quoin Pharmaceuticals, Ltd. | Anthony James Culverwell director | $45k 100,000 shares | first purchase | |
| 54Moderate | Quoin Pharmaceuticals, Ltd. | Gordon Dunn Chief Financial Officer | $55k 122,221 shares | +424% | |
| 63Notable | Quoin Pharmaceuticals, Ltd. | Michael Myers Chief Executive Officer | $250k 555,556 shares | +1176% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.